Randomized phase II trial of second-line FOLFIRI-panitumumab vs FOLFIRI alone in Ras wild type (wt) metastatic colorectal cancer (mCRC) patients beyond progression to first-line FOLFOX-panitumumab: BEYOND study (GEMCAD 17-01)

被引：0

作者：

Aparicio, J. ^{[1
]}

Virgili Manrique, A. C. ^{[2
]}

Capdevila, J. ^{[3
]}

Munoz Boza, F. ^{[4
]}

Galvan, P. ^{[5
]}

Richart, P. ^{[1
]}

Oliveres, H. ^{[6
]}

Paez, D. ^{[2
]}

Hernando, J. ^{[3
]}

Garcia Serrano, S. ^{[4
]}

Vera, R. ^{[7
]}

Hernandez, X. ^{[8
]}

Alvarez Gallego, R. ^{[9
]}

Riesco-Martinez, M. C. ^{[10
]}

Garcia de Albeniz, X. ^{[11
]}

Maurel, J. ^{[6
]}

机构：

[1] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain

[2] Hosp Santa Creu & Sant Pau, Med Oncol, Barcelona, Spain

[3] Vall dHebron Univ Hosp, Inst Oncol, Gastrointestinal & Endocrine Tumor Dept, Barcelona, Spain

[4] Hosp Univ St Joan Reus, Med Oncol, Reus, Spain

[5] Translat Genom & Targeted Therapies Solid Tumors, Barcelona, Spain

[6] Hosp Clin Barcelona, Dept Oncol, Barcelona, Spain

[7] Complejo Hosp Navarra, Med Oncol, Pamplona, Spain

[8] ICO, Med Oncol, Girona, Spain

[9] Hosp Madrid Norte San Chinarro, Ctr Integral Oncol Clara Campal, Med Oncol, Madrid, Spain

[10] Hosp Univ 12 Octubre, Med Oncol Dept, Madrid, Spain

[11] RTI Hlth Solut, Barcelona, Spain

来源：

关键词：

D O I：

10.1016/j.annonc.2021.08.937

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

416P

引用

页码：S543 / S543

页数：1